-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CBX-12 in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CBX-12 in Ovarian CancerDrug Details:CBX-12 is under development for the treatment of solid tumors including small cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CBX-12 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CBX-12 in Solid Tumor Drug Details:CBX-12 is under development for the treatment of solid tumors including small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CBX-12 in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CBX-12 in Small-Cell Lung CancerDrug Details:CBX-12 is under development for the treatment of solid tumors including small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASP-2138 in Adenocarcinoma Of The Gastroesophageal Junction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ASP-2138 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:ASP-2138 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INVA-8002 in Irritable Bowel Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INVA-8002 in Irritable Bowel Syndrome Drug Details:INVA-8002 is under development for the treatment of ulcerative colitis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-95775 in Basal Cell Carcinoma (Basal Cell Epithelioma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CC-95775 in Basal Cell Carcinoma (Basal Cell Epithelioma) Drug Details: CC-95775 (FT-1101) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bemarituzumab in Lung Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Bemarituzumab in Lung AdenocarcinomaDrug Details:Bemarituzumab [FPA-144] is under development for the treatment of solid tumors such...
-
Company Profile
![]()
Harvest Health & Recreation Inc – Company Profile
Harvest Health & Recreation Inc (Harvest Health), is a cannabis company. The company is engaged in cultivation, processing, distribution and sale of cannabis and cannabis related products. Harvest Health also owns CO2 extraction, distillation, purification, and manufacturing technology used to produce a line of cannabis topicals, vapes and gems featuring cannabinoids and a hemp-derived product. The company manufactures and distributes a portfolio of cannabis consumer packaged goods under brands, including ROLL ONE, MODERN FLOWER, GOODSUN, EVOLAB, CHROMA, CO2LORS, HARVEST, ALCHEMY...
Add to Basket -
Company Profile
![]()
Exelixis Inc – Company Profile
Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases, Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include zanzalintinib, XB002 and XL102 for the treatment of advanced or metastatic solid tumors and CBX-12 for advanced metastatic refractory...
Add to Basket -
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – CBX-12
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CBX-12 Drug Details CBX-12 is under development for the treatment of solid tumors including small...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.